Humanin vs MOTS-c
A side-by-side look at two popular peptides and how they compare.
Overview
Humanin and MOTS-c are both mitochondrial-derived peptides (MDPs), making them unique in the peptide landscape as molecules encoded within the mitochondrial rather than nuclear genome. Humanin was the first MDP discovered and is associated with neuroprotective and cytoprotective effects, while MOTS-c is primarily associated with metabolic regulation. Together they represent the emerging field of mitochondrial peptide biology. Their comparison reveals how the mitochondria communicate with the rest of the cell through different signaling molecules.
Humanin
Humanin is a 24-amino-acid peptide encoded in the mitochondrial 16S rRNA gene, discovered in 2001 from studies of Alzheimer's-resilient brain tissue. It has been associated with cytoprotection against cellular stress, neuroprotection, and insulin sensitization. Humanin is commonly sought for its neuroprotective properties and potential role in supporting cellular resilience against age-related decline.
MOTS-c
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene, representing the second major mitochondrial-derived peptide discovery. It has been associated with AMPK activation, metabolic regulation, and exercise-mimetic effects on muscle and fat tissue. MOTS-c is commonly sought for metabolic optimization, insulin sensitivity support, and cellular energy enhancement.
Side-by-Side Comparison
| Category | Humanin | MOTS-c |
|---|---|---|
| Primary Focus | Neuroprotection and cytoprotection against cellular stress | Metabolic regulation and exercise-mimetic effects |
| How It Works | Activates STAT3, inhibits Bax-mediated apoptosis, binds IGFBP-3 | Activates AMPK, regulates folate-methionine cycle, enhances fat oxidation |
| Discovery Context | Found in brain tissue resistant to neurodegenerative decline | Identified through computational analysis of mitochondrial genome |
| Target Tissues | Brain, cardiovascular system, pancreatic beta cells | Skeletal muscle, adipose tissue, metabolic organs |
| Who It's For | Those focused on neuroprotection and cellular stress resilience | Those focused on metabolic health and body composition |
| Research Status | Published since 2001; growing interest in aging research | Published since 2015; rapidly expanding research base |
Key Differences
Humanin is primarily associated with protective effects against cellular death and neurodegeneration, while MOTS-c is focused on metabolic regulation and energy homeostasis. They work through entirely different signaling pathways despite both being mitochondrial in origin. Humanin has a longer research history but is less commercially discussed, while MOTS-c has gained faster traction in the wellness community due to its metabolic applications.
Key Similarities
Both are mitochondrial-derived peptides, a rare and fascinating class of signaling molecules. They each decline with age, and this decline has been associated with aspects of aging and metabolic dysfunction. Both represent the concept of mitochondrial-nuclear communication, where mitochondria send peptide signals that influence whole-body physiology.
Which One Might Be Right for You?
Humanin may be more relevant for individuals primarily interested in cognitive wellness, neuroprotective support, and cellular stress resilience. MOTS-c is likely more appropriate for those focused on metabolic health, body composition, and insulin sensitivity optimization. As mitochondrial health underlies both applications, some researchers discuss the potential value of supporting both pathways. Individual health priorities and provider guidance should inform selection.
Humanin vs MOTS-c FAQ
For Patients
Looking for peptide therapy? Get matched with a qualified provider near you.
Related Pages
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Peptide therapies should only be administered by licensed healthcare providers. Always consult with a qualified healthcare professional before starting any new treatment. PeptideLeads is a marketing agency and does not provide medical services.